Get started
Verrica Pharmaceuticals Inc.Verrica Pharmaceuticals Inc.Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

VRCA chart


Full chart

VRCA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪42.95 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.5360 USD
Net income (FY)
‪−76.58 M‬ USD
Revenue (FY)
‪7.57 M‬ USD
Shares float
‪49.69 M‬
Beta (1Y)
−0.65

Employees


Employees (FY)
71
Change (1Y)
−29 −29.00%
Revenue / Employee (1Y)
‪106.56 K‬ USD
Net income / Employee (1Y)
‪−1.08 M‬ USD

About Verrica Pharmaceuticals Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Jayson M. Rieger
Website
verrica.com
Headquarters
West Chester
Founded
2013
FIGI
BBG00L03BYB7
Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

VRCA news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as VRCA.

Frequently Asked Questions


The current price of VRCA is 0.4587 USD — it has increased by 0.56% in the past 24 hours. Watch Verrica Pharmaceuticals Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Verrica Pharmaceuticals Inc. stocks are traded under the ticker VRCA.
VRCA stock has fallen by −19.45% compared to the previous week, the month change is a −22.00% fall, over the last year Verrica Pharmaceuticals Inc. has showed a −93.23% decrease.
We've gathered analysts' opinions on Verrica Pharmaceuticals Inc. future price: according to them, VRCA price has a max estimate of 5.00 USD and a min estimate of 2.00 USD. Watch VRCA chart and read a more detailed Verrica Pharmaceuticals Inc. stock forecast: see what analysts think of Verrica Pharmaceuticals Inc. and suggest that you do with its stocks.
VRCA reached its all-time high on Jun 20, 2018 with the price of 23.2900 USD, and its all-time low was 0.3816 USD and was reached on Apr 3, 2025. View more price dynamics on VRCA chart.
See other stocks reaching their highest and lowest prices.
VRCA stock is 10.94% volatile and has beta coefficient of −0.65. Track Verrica Pharmaceuticals Inc. stock price on the chart and check out the list of the most volatile stocks — is Verrica Pharmaceuticals Inc. there?
Today Verrica Pharmaceuticals Inc. has the market capitalization of ‪42.95 M‬, it has increased by 1.34% over the last week.
Yes, you can track Verrica Pharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
Verrica Pharmaceuticals Inc. is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
VRCA earnings for the last quarter are −0.24 USD per share, whereas the estimation was −0.25 USD resulting in a 4.00% surprise. The estimated earnings for the next quarter are −0.13 USD per share. See more details about Verrica Pharmaceuticals Inc. earnings.
Verrica Pharmaceuticals Inc. revenue for the last quarter amounts to ‪344.00 K‬ USD, despite the estimated figure of ‪1.04 M‬ USD. In the next quarter, revenue is expected to reach ‪2.54 M‬ USD.
VRCA net income for the last quarter is ‪−16.20 M‬ USD, while the quarter before that showed ‪−22.86 M‬ USD of net income which accounts for 29.13% change. Track more Verrica Pharmaceuticals Inc. financial stats to get the full picture.
No, VRCA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 24, 2025, the company has 71 employees. See our rating of the largest employees — is Verrica Pharmaceuticals Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Verrica Pharmaceuticals Inc. EBITDA is ‪−63.75 M‬ USD, and current EBITDA margin is −840.76%. See more stats in Verrica Pharmaceuticals Inc. financial statements.
Like other stocks, VRCA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Verrica Pharmaceuticals Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Verrica Pharmaceuticals Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Verrica Pharmaceuticals Inc. stock shows the sell signal. See more of Verrica Pharmaceuticals Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.